Taglietti Marco 4

What Happened
Marco Taglietti, a director of Aquestive Therapeutics (AQST), received a derivative award on June 10, 2026 covering 50,500 shares. The reported acquisition price is $0.00, indicating a grant of options (not an open-market purchase). The options do not vest immediately — the filing shows the underlying shares vest 100% on June 10, 2027, contingent on Dr. Taglietti’s continued service through the vesting date. This is a grant (potentially a retention/incentive award), which is different from an immediate purchase or sale and is typically meant to align long-term incentives.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (filed timely).
• Transaction type: Grant/Award of a derivative instrument (options) covering 50,500 shares; reported price $0.00.
• Vesting: 100% of underlying shares vest on June 10, 2027, subject to continuous service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of an immediate sale or cashless exercise — this is a standard future-vesting option grant.

Context
Because this is a derivative grant that vests in one year, it does not represent immediate stock purchases or sales and therefore is a forward-looking compensation event rather than an immediate insider market action. Such awards are commonly used for retention and long-term alignment; they only translate into actual shares if vesting conditions are met and any exercise is completed.